Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, October 2004, p. 4027-4032, Vol. 48, No. 10
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.10.4027-4032.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents
Lois M. Ednie, Glenn Pankuch, and Peter C. Appelbaum*
Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania
Received 4 June 2004/
Returned for modification 16 June 2004/
Accepted 24 June 2004
The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 µg/ml for 300 pneumococci, irrespective of their ß-lactam, macrolide, and quinolone susceptibilities. By comparison, vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin were also active, with MICs
2.0 µg/ml. Gatifloxacin and moxifloxacin were the most active quinolones tested, while the MICs of the ß-lactams rose with those of penicillin G. LBM415 at two times the MIC was bactericidal (99.9% killing) against six strains after 24 h.
* Corresponding author. Mailing address: Department of Pathology, Penn State Hershey Medical Center, 500 University Dr., H160, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psu.edu.
Antimicrobial Agents and Chemotherapy, October 2004, p. 4027-4032, Vol. 48, No. 10
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.10.4027-4032.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Kosowska-Shick, K., Credito, K. L., Pankuch, G. A., DeWasse, B., McGhee, P., Appelbaum, P. C.
(2007). Multistep Resistance Selection and Postantibiotic-Effect Studies of the Antipneumococcal Activity of LBM415 Compared to Other Agents. Antimicrob. Agents Chemother.
51: 770-773
[Abstract]
[Full Text]
-
Bogdanovich, T., Smith, K. A., Clark, C., Pankuch, G. A., Lin, G., McGhee, P., Dewasse, B., Appelbaum, P. C.
(2006). Activity of LBM415 Compared to Those of 11 Other Agents against Haemophilus Species.. Antimicrob. Agents Chemother.
50: 2323-2329
[Abstract]
[Full Text]
-
Watters, A. A., Jones, R. N., Leeds, J. A., Denys, G., Sader, H. S., Fritsche, T. R.
(2006). Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J Antimicrob Chemother
57: 914-923
[Abstract]
[Full Text]
-
Fonseca-Aten, M., Salvatore, C. M., Mejias, A., Rios, A. M., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr, Hardy, R. D.
(2005). Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother.
49: 4128-4136
[Abstract]
[Full Text]
-
Fritsche, T. R., Sader, H. S., Cleeland, R., Jones, R. N.
(2005). Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance. Antimicrob. Agents Chemother.
49: 1468-1476
[Abstract]
[Full Text]
-
Bell, J. M., Turnidge, J. D., Inoue, M., Kohno, S., Hirakata, Y., Ono, Y., Jones, R. N.
(2005). Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J Antimicrob Chemother
55: 276-278
[Full Text]
Copyright © 2004 by the American Society for Microbiology. All rights reserved.